Physician profile
John Gordon
NPI 1801980479
$535.42
in general payments reported to CMS, 2019-2025
9 companies · $22.69 in 2025
The $22.69 reported for 2025 was less than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $23.84 · 2021: $72.71 · 2022: $57.57 · 2023: $140 · 2024: $118 · 2025: $22.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $280.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $111.63 | 2021-2022 | |
| Organon LLC | $100.27 | 2023-2024 | Follistim Aq, Pregnyl, Ganirelix Acetate |
| Coopersurgical, INC. | $91.16 | 2023-2024 | Stripper, Origio Sequential Fert |
| Ferring Pharmaceuticals INC. | $90.72 | 2019-2023 | Menopur |
| Emd Serono, INC. | $47.80 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $41.12 | 2023 | Myfembree |
| Fujifilm Holdings America Corporation | $22.69 | 2025 | |
| Merck Sharp & Dohme LLC | $17.92 | 2019 | |
| Guerbet LLC | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.